OB/GYN Clinical Alert – May 1, 2004
May 1, 2004
View Issues
-
More from the Women’s Health Initiative
The latest news from the womens health initiative (WHI) includes 3 noteworthy reports: the news release announcing the cancellation of the estrogen-only arm of the clinical trial,1 a comparison of the participants in the 2 clinical trial arms(estrogen-progestin and estrogen-only),2 and the updated, adjudicated lorectal cancer results from the estrogen-progestin arm.3 -
Restaging Surgery for Women with Borderline Ovarian Tumors: Results of a French Mulitcenter Study
Women who initially were diagnosed with Stage IA disease and who had serous borderline tumors or underwent cystectomy appeared to derive the most benefit from restaging surgery. Nonetheless, the indications for restaging surgery remain controversial, as no difference in recurrence rate was observed between women who underwent restaging and those who did not. -
Special Feature: Non-Invasive Approach to Prenatal Diagnosis
In this special feature, up-to-date information will be provided regarding the risks and benefits of various diagnostic methods available today for patients of advanced maternal age (AMA). -
Clinical Briefs in Primary Care
-
Pharmacology Watch: Atherosclerosis Reversed With Lipid-Lowering Drugs
Positive Alendronate Data in Osteoporosis; NSAIDs For Myocardial Infarction; Four-Hour Window for CAP Patients; FDA Actions.